The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gestational Trophoblastic Disease Market Research Report 2024
Synopsis
Gestational trophoblastic disease (GTD) is a group of rare diseases in which abnormal trophoblast cells grow inside the uterus after conception. In gestational trophoblastic disease (GTD), a tumor develops inside the uterus from tissue that forms after conception (the joining of sperm and egg).
Global Gestational Trophoblastic Disease market is projected to reach US$ 2587.6 million in 2029, increasing from US$ 1940 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gestational Trophoblastic Disease market research.
The global gestational trophoblastic disease (GTD) market refers to the market for diagnostic tests, treatments, and management strategies aimed at addressing GTD, a group of rare tumors that arise in the cells of the placenta during pregnancy. GTD includes conditions such as hydatidiform mole, gestational trophoblastic neoplasia, and choriocarcinoma.
The market for GTD is driven by several factors, including the increasing incidence of these diseases, advancements in diagnostic techniques, and improvements in treatment options. Early detection and accurate diagnosis are crucial for effective management of GTD. Diagnostic methods include ultrasound, human chorionic gonadotropin (hCG) measurement, and histopathological examination.
The primary treatment for GTD is the surgical removal of the affected tissue, which is often followed by chemotherapy in cases of gestational trophoblastic neoplasia and choriocarcinoma. Methotrexate is commonly used as a chemotherapy drug, and other chemotherapeutic agents may also be employed depending on the stage and type of the disease. In cases of high-risk or resistant GTD, additional treatments such as radiation therapy may be recommended.
Geographically, North America and Europe hold a significant share in the global GTD market, primarily due to factors such as well-established healthcare infrastructure, advanced diagnostic technologies, and increased awareness about GTD. Asia-Pacific is also experiencing growth in the GTD market, attributed to factors such as rising healthcare expenditure, improving healthcare infrastructure, and increasing awareness about women’s health.
Key players in the global GTD market include pharmaceutical companies, diagnostic test manufacturers, and healthcare providers specializing in women’s health. These companies focus on developing innovative diagnostic tests, drugs, and treatment protocols to improve patient outcomes and ensure better management of GTD.
However, challenges in the GTD market include the rarity of these diseases, leading to limited awareness and expertise among healthcare professionals, as well as the potential for complications and the need for individualized treatment approaches. Additionally, the emotional and psychological impact of GTD on patients and their families is an area that requires attention and support.
In summary, the global gestational trophoblastic disease market is driven by factors such as the increasing incidence of these rare tumors, advancements in diagnostic techniques, and improvements in treatment options. North America and Europe currently lead the market, but Asia-Pacific is witnessing growth. Key players in the market continue to invest in research and development to improve diagnostic accuracy, develop targeted therapies, and ensure optimal management of GTD.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Gestational Trophoblastic Disease market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bristol Myers Squibb
Antares Pharma
Novartis AG
Accord Healthcare Limited
Eli Lilly and Company
Sanofi
Bayer AG
Amgen
Merck KGaA
Teva Pharmaceuticals
B.P Pharma
Segment by Type
Chemotherapy
Surgery
Radiation Therapy
Others
Segment by Application
Hospitals
Clinics
Cancer Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Gestational Trophoblastic Disease report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Gestational trophoblastic disease (GTD) is a group of rare diseases in which abnormal trophoblast cells grow inside the uterus after conception. In gestational trophoblastic disease (GTD), a tumor develops inside the uterus from tissue that forms after conception (the joining of sperm and egg).
Global Gestational Trophoblastic Disease market is projected to reach US$ 2587.6 million in 2029, increasing from US$ 1940 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gestational Trophoblastic Disease market research.
The global gestational trophoblastic disease (GTD) market refers to the market for diagnostic tests, treatments, and management strategies aimed at addressing GTD, a group of rare tumors that arise in the cells of the placenta during pregnancy. GTD includes conditions such as hydatidiform mole, gestational trophoblastic neoplasia, and choriocarcinoma.
The market for GTD is driven by several factors, including the increasing incidence of these diseases, advancements in diagnostic techniques, and improvements in treatment options. Early detection and accurate diagnosis are crucial for effective management of GTD. Diagnostic methods include ultrasound, human chorionic gonadotropin (hCG) measurement, and histopathological examination.
The primary treatment for GTD is the surgical removal of the affected tissue, which is often followed by chemotherapy in cases of gestational trophoblastic neoplasia and choriocarcinoma. Methotrexate is commonly used as a chemotherapy drug, and other chemotherapeutic agents may also be employed depending on the stage and type of the disease. In cases of high-risk or resistant GTD, additional treatments such as radiation therapy may be recommended.
Geographically, North America and Europe hold a significant share in the global GTD market, primarily due to factors such as well-established healthcare infrastructure, advanced diagnostic technologies, and increased awareness about GTD. Asia-Pacific is also experiencing growth in the GTD market, attributed to factors such as rising healthcare expenditure, improving healthcare infrastructure, and increasing awareness about women’s health.
Key players in the global GTD market include pharmaceutical companies, diagnostic test manufacturers, and healthcare providers specializing in women’s health. These companies focus on developing innovative diagnostic tests, drugs, and treatment protocols to improve patient outcomes and ensure better management of GTD.
However, challenges in the GTD market include the rarity of these diseases, leading to limited awareness and expertise among healthcare professionals, as well as the potential for complications and the need for individualized treatment approaches. Additionally, the emotional and psychological impact of GTD on patients and their families is an area that requires attention and support.
In summary, the global gestational trophoblastic disease market is driven by factors such as the increasing incidence of these rare tumors, advancements in diagnostic techniques, and improvements in treatment options. North America and Europe currently lead the market, but Asia-Pacific is witnessing growth. Key players in the market continue to invest in research and development to improve diagnostic accuracy, develop targeted therapies, and ensure optimal management of GTD.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Gestational Trophoblastic Disease market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bristol Myers Squibb
Antares Pharma
Novartis AG
Accord Healthcare Limited
Eli Lilly and Company
Sanofi
Bayer AG
Amgen
Merck KGaA
Teva Pharmaceuticals
B.P Pharma
Segment by Type
Chemotherapy
Surgery
Radiation Therapy
Others
Segment by Application
Hospitals
Clinics
Cancer Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Gestational Trophoblastic Disease report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gestational Trophoblastic Disease Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Chemotherapy
1.2.3 Surgery
1.2.4 Radiation Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Gestational Trophoblastic Disease Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Cancer Research Institutes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gestational Trophoblastic Disease Market Perspective (2018-2029)
2.2 Gestational Trophoblastic Disease Growth Trends by Region
2.2.1 Global Gestational Trophoblastic Disease Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Gestational Trophoblastic Disease Historic Market Size by Region (2018-2023)
2.2.3 Gestational Trophoblastic Disease Forecasted Market Size by Region (2024-2029)
2.3 Gestational Trophoblastic Disease Market Dynamics
2.3.1 Gestational Trophoblastic Disease Industry Trends
2.3.2 Gestational Trophoblastic Disease Market Drivers
2.3.3 Gestational Trophoblastic Disease Market Challenges
2.3.4 Gestational Trophoblastic Disease Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gestational Trophoblastic Disease Players by Revenue
3.1.1 Global Top Gestational Trophoblastic Disease Players by Revenue (2018-2023)
3.1.2 Global Gestational Trophoblastic Disease Revenue Market Share by Players (2018-2023)
3.2 Global Gestational Trophoblastic Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gestational Trophoblastic Disease Revenue
3.4 Global Gestational Trophoblastic Disease Market Concentration Ratio
3.4.1 Global Gestational Trophoblastic Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gestational Trophoblastic Disease Revenue in 2022
3.5 Gestational Trophoblastic Disease Key Players Head office and Area Served
3.6 Key Players Gestational Trophoblastic Disease Product Solution and Service
3.7 Date of Enter into Gestational Trophoblastic Disease Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gestational Trophoblastic Disease Breakdown Data by Type
4.1 Global Gestational Trophoblastic Disease Historic Market Size by Type (2018-2023)
4.2 Global Gestational Trophoblastic Disease Forecasted Market Size by Type (2024-2029)
5 Gestational Trophoblastic Disease Breakdown Data by Application
5.1 Global Gestational Trophoblastic Disease Historic Market Size by Application (2018-2023)
5.2 Global Gestational Trophoblastic Disease Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Gestational Trophoblastic Disease Market Size (2018-2029)
6.2 North America Gestational Trophoblastic Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Gestational Trophoblastic Disease Market Size by Country (2018-2023)
6.4 North America Gestational Trophoblastic Disease Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gestational Trophoblastic Disease Market Size (2018-2029)
7.2 Europe Gestational Trophoblastic Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Gestational Trophoblastic Disease Market Size by Country (2018-2023)
7.4 Europe Gestational Trophoblastic Disease Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gestational Trophoblastic Disease Market Size (2018-2029)
8.2 Asia-Pacific Gestational Trophoblastic Disease Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Gestational Trophoblastic Disease Market Size by Region (2018-2023)
8.4 Asia-Pacific Gestational Trophoblastic Disease Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gestational Trophoblastic Disease Market Size (2018-2029)
9.2 Latin America Gestational Trophoblastic Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Gestational Trophoblastic Disease Market Size by Country (2018-2023)
9.4 Latin America Gestational Trophoblastic Disease Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gestational Trophoblastic Disease Market Size (2018-2029)
10.2 Middle East & Africa Gestational Trophoblastic Disease Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Gestational Trophoblastic Disease Market Size by Country (2018-2023)
10.4 Middle East & Africa Gestational Trophoblastic Disease Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol Myers Squibb
11.1.1 Bristol Myers Squibb Company Detail
11.1.2 Bristol Myers Squibb Business Overview
11.1.3 Bristol Myers Squibb Gestational Trophoblastic Disease Introduction
11.1.4 Bristol Myers Squibb Revenue in Gestational Trophoblastic Disease Business (2018-2023)
11.1.5 Bristol Myers Squibb Recent Development
11.2 Antares Pharma
11.2.1 Antares Pharma Company Detail
11.2.2 Antares Pharma Business Overview
11.2.3 Antares Pharma Gestational Trophoblastic Disease Introduction
11.2.4 Antares Pharma Revenue in Gestational Trophoblastic Disease Business (2018-2023)
11.2.5 Antares Pharma Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Detail
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Gestational Trophoblastic Disease Introduction
11.3.4 Novartis AG Revenue in Gestational Trophoblastic Disease Business (2018-2023)
11.3.5 Novartis AG Recent Development
11.4 Accord Healthcare Limited
11.4.1 Accord Healthcare Limited Company Detail
11.4.2 Accord Healthcare Limited Business Overview
11.4.3 Accord Healthcare Limited Gestational Trophoblastic Disease Introduction
11.4.4 Accord Healthcare Limited Revenue in Gestational Trophoblastic Disease Business (2018-2023)
11.4.5 Accord Healthcare Limited Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Detail
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Gestational Trophoblastic Disease Introduction
11.5.4 Eli Lilly and Company Revenue in Gestational Trophoblastic Disease Business (2018-2023)
11.5.5 Eli Lilly and Company Recent Development
11.6 Sanofi
11.6.1 Sanofi Company Detail
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Gestational Trophoblastic Disease Introduction
11.6.4 Sanofi Revenue in Gestational Trophoblastic Disease Business (2018-2023)
11.6.5 Sanofi Recent Development
11.7 Bayer AG
11.7.1 Bayer AG Company Detail
11.7.2 Bayer AG Business Overview
11.7.3 Bayer AG Gestational Trophoblastic Disease Introduction
11.7.4 Bayer AG Revenue in Gestational Trophoblastic Disease Business (2018-2023)
11.7.5 Bayer AG Recent Development
11.8 Amgen
11.8.1 Amgen Company Detail
11.8.2 Amgen Business Overview
11.8.3 Amgen Gestational Trophoblastic Disease Introduction
11.8.4 Amgen Revenue in Gestational Trophoblastic Disease Business (2018-2023)
11.8.5 Amgen Recent Development
11.9 Merck KGaA
11.9.1 Merck KGaA Company Detail
11.9.2 Merck KGaA Business Overview
11.9.3 Merck KGaA Gestational Trophoblastic Disease Introduction
11.9.4 Merck KGaA Revenue in Gestational Trophoblastic Disease Business (2018-2023)
11.9.5 Merck KGaA Recent Development
11.10 Teva Pharmaceuticals
11.10.1 Teva Pharmaceuticals Company Detail
11.10.2 Teva Pharmaceuticals Business Overview
11.10.3 Teva Pharmaceuticals Gestational Trophoblastic Disease Introduction
11.10.4 Teva Pharmaceuticals Revenue in Gestational Trophoblastic Disease Business (2018-2023)
11.10.5 Teva Pharmaceuticals Recent Development
11.11 B.P Pharma
11.11.1 B.P Pharma Company Detail
11.11.2 B.P Pharma Business Overview
11.11.3 B.P Pharma Gestational Trophoblastic Disease Introduction
11.11.4 B.P Pharma Revenue in Gestational Trophoblastic Disease Business (2018-2023)
11.11.5 B.P Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
